Overview

A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis

Status:
Completed
Trial end date:
2020-11-19
Target enrollment:
Participant gender:
Summary
A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC
XBiotech, Inc.
Treatments:
Antibodies
Antibodies, Monoclonal